Table 4.

Effect of chronic administration of Vigiis 101-LAB capsule II or placebo on immunoassay, antioxidant capacity, and the GSH redox cycle profiles of subjects (clinical trial II).

		Treatment group			Placebo group
		Initial (0 wk)	Administration (4 wk)	Follow-up (6 wk)	Initial (0 wk)	Administration (4 wk)	Follow-up (6 wk)
Hs-CRP	(mg/dL)	0.09 ± 0.09	0.08 ± 0.06	0.09 ± 0.09	0.18 ± 0.24	0.09 ± 0.10	0.14 ± 0.16
IgG		1190.3 ± 180.5	1230.6 ± 178.4∗	1215.2 ± 176.8∗	1217.7 ± 160.0	1260.6 ± 184.6	1275.8 ± 159.4
IgM		132.1 ± 36.3	141.0 ± 41.5∗	134.1 ± 40.6	123.3 ± 42.7	128.4 ± 45.7	128.1 ± 44.7
IgE	(IU/mL)	83.6 ± 173.1	84.0 ± 73.7	89.1 ± 79.3∗	109.2 ± 94.2	118.1 ± 106.4	120.3 ± 106.7
GSH	(ng/μL)	31.6 ± 2.6	33.0 ± 4.8∗	37.0 ± 2.0∗	29.5 ± 3.0	30.2 ± 2.6	31.4 ± 1.6
GSH Px	(mU/mL)	86.2 ± 16.0	135.8 ± 36.6∗	113.5 ± 12.3∗	88.9 ± 17.6	94.3 ± 7.3	95.6 ± 24.0
GSH Rd		42.2 ± 0.2	49.9 ± 0.4∗	48.2 ± 1.9∗	42.5 ± 0.3	42.7 ± 0.4	42.6 ± 0.2
TEAC	(μg Trolox eq./mg)	6.60 ± 0.04	6.70 ± 0.05∗	6.70 ± 0.07∗	6.60 ± 0.06	6.60 ± 0.06	6.60 ± 0.06
TBARS	(μM)	0.71 ± 0.17	0.43 ± 0.09∗	0.32 ± 0.07∗	0.51 ± 0.14	0.68 ± 0.30	0.51 ± 0.12
		Treatment			Placebo
		Initial	Week 4	p-value	Initial	Week 4	p-value
Gut transit times		107.2 ± 29.3 min	80.6 ± 33.7∗min	0.004	82.8 ± 48.9 min	99.0 ± 34.1 min	0.052

Hs-CRP: high-sensitivity C-reactive protein; IgG: immunoglobulin G; IgM: immunoglobulin M; IgE: Immunoglobulin E; GSH: glutathione; GSH Px: glutathione peroxidase; GSH Rd: glutathione reductase; TEAC: Trolox equivalent antioxidant capacity; TBARs: thiobarbituric acid reactive substances. Student's t-test, no significant difference between placebo and treatment groups at week 0. Values are mean ± SD (treatment group: n = 27; placebo group: n = 25). ∗ Significantly different from the initial value (P < 0.05).